Online citations, reference lists, and bibliographies.
← Back to Search

Prediction Of Response To Preoperative Chemotherapy In Adenocarcinomas Of The Esophagogastric Junction By Metabolic Imaging.

W. Weber, K. Ott, K. Becker, H. J. Dittler, H. Helmberger, N. Avril, G. Meisetschläger, R. Busch, J. Siewert, M. Schwaiger, U. Fink
Published 2001 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PURPOSE Preoperative chemotherapy in patients with gastroesophageal cancer is hampered by the lack of reliable predictors of tumor response. This study evaluates whether positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) may predict response early in the course of therapy. PATIENTS AND METHODS Forty consecutive patients with locally advanced adenocarcinomas of the esophagogastric junction were studied by FDG-PET at baseline and 14 days after initiation of cisplatin-based polychemotherapy. Clinical response (reduction of tumor length and wall thickness by > 50%) was evaluated after 3 months of therapy using endoscopy and standard imaging techniques. Patients with potentially resectable tumors underwent surgery, and tumor regression was assessed histopathologically. RESULTS The reduction of tumor FDG uptake (mean +/- 1 SD) after 14 days of therapy was significantly different between responding (-54% +/- 17%) and nonresponding tumors (-15% +/- 21%). Optimal differentiation was achieved by a cutoff value of 35% reduction of initial FDG uptake. Applying this cutoff value as a criterion for a metabolic response predicted clinical response with a sensitivity and specificity of 93% (14 of 15 patients) and 95% (21 of 22), respectively. Histopathologically complete or subtotal tumor regression was achieved in 53% (eight of 15) of the patients with a metabolic response but only in 5% (one of 22) of the patients without a metabolic response. Patients without a metabolic response were also characterized by significantly shorter time to progression/recurrence (P =.01) and shorter overall survival (P =.04). CONCLUSION PET imaging may differentiate responding and nonresponding tumors early in the course of therapy. By avoiding ineffective and potentially harmful treatment, this may markedly facilitate the use of preoperative therapy, especially in patients with potentially resectable tumors.
This paper references
10.1016/S0003-4975(99)00974-1
Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans.
J. Luketich (1999)
10.1182/BLOOD.V91.12.4464
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
W. Römer (1998)
10.1002/(SICI)1097-0142(19980701)83:1<7::AID-CNCR2>3.0.CO;2-R
p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma
U. Ribeiro (1998)
10.1002/(SICI)1097-0142(20000415)88:8<1788::AID-CNCR5>3.0.CO;2-6
Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients
A. Chak (2000)
10.1046/J.1365-2168.1998.00940.X
Classification of adenocarcinoma of the oesophagogastric junction
J. Siewert (1998)
10.2214/AJR.168.2.9016218
Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.
F. Flanagan (1997)
10.1097/00000658-200009000-00007
Adenocarcinoma of the Esophagogastric Junction: Results of Surgical Therapy Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients
J. Rüdiger Siewert (2000)
10.1016/0720-048X(96)01028-5
Adenocarcinoma of the gastro-esophageal junction: CT for monitoring during neoadjuvant chemotherapy.
H. Helmberger (1996)
Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice.
T. Yoshioka (1997)
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
10.1046/J.1365-2168.1998.00915.X
Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules
H. Präuer (1998)
10.1056/NEJM199812313392704
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
D. Kelsen (1998)
10.1200/JCO.2000.18.18.3202
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
P. Flamen (2000)
10.1016/S0959-8049(97)00094-4
Pre-operative chemotherapy for squamous cell carcinoma of the oesophagus: do histological assessment and p53 overexpression predict chemo-responsiveness?
K. Lam (1997)
10.1016/S0009-9260(98)80270-5
Correlation of CT with histopathological findings in patients with gastric and gastro-oesophageal carcinomas following neoadjuvant chemotherapy.
C. Ng (1998)
10.1093/OXFORDJOURNALS.ANNONC.A057992
Zürich experience in osteogenic sarcoma: state of the art--past, present or future?
G. Rosen (1991)
10.1200/JCO.1998.16.1.309
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
R. Metzger (1998)
10.1200/JCO.1996.14.1.176
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
H. Lenz (1996)
10.1002/(SICI)1098-2388(199909)17:2<125::AID-SSU7>3.0.CO;2-9
Surgical resection for cancer of the cardia.
J. Siewert (1999)
10.1200/JCO.2000.18.8.1689
Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer
M. Schelling (2000)
Reproducibility of metabolic measurements in malignant tumors using FDG PET.
W. Weber (1999)
10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations
A. Mandard (1994)
10.1097/00004424-198903000-00012
Some practical issues of experimental design and data analysis in radiological ROC studies.
C. Metz (1989)
10.1055/S-2007-1009101
Response to chemotherapy in esophageal cancer.
H. J. Dittler (1994)
10.1016/S0959-8049(99)00229-4
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H. Young (1999)
10.1016/S0022-5223(19)35265-1
Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus.
J. Roth (1988)
10.1016/S0016-5107(98)70157-9
Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation.
G. Isenberg (1998)
10.1200/JCO.1996.14.3.700
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
M. Findlay (1996)
10.1097/00000658-199903000-00001
Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer.
A. Lowy (1999)
10.1016/S0959-8049(97)00356-0
Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy.
K. Nooter (1998)
10.1016/S0022-5223(97)70147-8
Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial.
S. Law (1997)



This paper is referenced by
10.1111/j.1600-0609.2006.00675.x
Effect of drug‐induced cytotoxicity on glucose uptake in Hodgkin's lymphoma cells
U. Banning (2006)
10.1586/14737140.8.12.1953
Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction
G. Ku (2008)
10.1007/978-3-319-26067-9_19-1
Diagnostic Applications of Nuclear Medicine: Colorectal Cancer
Ettore Pelosi (2016)
10.1016/B978-0-323-48567-8.00004-3
Chapter 4 – Gastroesophageal Cancer
A. Rezaee (2018)
10.1002/cncr.30028
Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma
G. Ku (2016)
10.1016/j.ctro.2017.01.008
Follow up results of a prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer
S. P. Ng (2017)
10.1200/JCO.2006.06.7801
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
K. Ott (2006)
10.1007/s00761-005-0881-x
Neoadjuvante Therapie beim lokal fortgeschrittenen Magenkarzinom
F. Lordick (2005)
10.1016/J.SEMRADONC.2006.09.001
Considerations in treatment planning for esophageal cancer.
T. Hong (2007)
10.1023/A:1023581731443
Clinical Trial Design for Target Specific Anticancer Agents
R. Hoekstra (2004)
10.1007/s00259-004-1626-6
Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET
A. Stahl (2004)
Factores predictores del grado de regresión tumoral en los tumores gástricos localmente avanzados
Sánchez de Molina Rampérez (2018)
10.4251/wjgo.v1.i1.34
Positron emission tomography's changing significance in the treatment of esophageal cancer.
S. Hopkins (2009)
10.1158/1078-0432.CCR-06-3025
Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
K. Herrmann (2007)
10.1016/J.IJROBP.2007.03.053
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
A. Konski (2007)
10.1111/j.1440-1746.2009.05838.x
Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
H. Elsaleh (2009)
10.1102/1470-7330.2013.9039
Predicting tumour response
Samuel Kyle (2013)
10.3389/fonc.2019.00471
Radiologic Modalities and Response Assessment Schemes for Clinical and Preclinical Oncology Imaging
F. Faraji (2019)
10.1002/9781118512074.CH150
Radionuclide Imaging in the Gastrointestinal Tract
H. Ziessman (2015)
10.2298/AOO1204086M
Positron emission tomography in neoplasms of the digestive system
J. Mihailovič (2012)
10.1002/bjs.4575
Neoadjuvant therapy for oesophagogastric cancer
F. Lordick (2004)
10.1002/cncr.26122
Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy
A. Suzuki (2011)
10.1097/MNM.0000000000000810
Evaluation of 18F-FDG PET-CT as a prognostic marker in advanced biliary tract cancer
M. Braghiroli (2018)
10.1136/gut.52.suppl_4.iv23
18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies
B. Chin (2003)
10.1007/978-0-387-48902-5_17
PET-CT of Esophageal Cancer
G. Cook (2011)
10.1120/jacmp.v9i3.2747
Time‐course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow
A. Kesner (2008)
10.1097/01.JTO.0000275339.62831.5E
Radiochemotherapy of esophageal cancer.
Z. Liao (2007)
10.1007/s00104-006-1163-x
Therapeutische Strategien bei lokoregionalen Rezidiven gastrointestinaler Tumoren
J. Siewert (2006)
Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas.
H. Kato (2005)
10.1002/9780470571224.PSE288
Optimizing the Use of Biomarkers for Drug Development: A Clinician's Perspective
A. Gimona (2010)
10.1634/theoncologist.2008-0119
Measuring response with FDG-PET: methodological aspects.
M. Allen-Auerbach (2009)
10.1038/ncpgasthep1366
Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers
K. Herrmann (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar